Background: To evaluate the pharmacokinetic properties of daily oral doses of tamsulosin administered to fasted healthy Korean male volunteers for 5 days. Methods: In a randomized, open-label, multiple-dose, two-period, crossover study, all 44 subjects were randomly assigned in a 1:1 ratio to receive a newly developed generic capsule formulation (test) or a branded capsule formulation (reference) of tamsulosin 0.2 mg, followed by a 10-day washout period and administration of the other formulation. Plasma concentrations of tamsulosin were assessed after administration of five-day multiple doses, using HPLC-MS/MS. Clinical and laboratory adverse events (AE) were assessed. Results: The mean (SD) pharmacokinetic properties with the test and reference formulations were as follows: C ss, max , 9.0 (2.9) and 8.4 (2.6) ng/mL, respectively; median (range) t max , 4 (2-6) and 5 (2-7) hours; AUC τ , 93.7 (31.5) and 88.2 (29.3) ng × h/mL; and t ½ , 9.5 (2.6) and 10.0 (2.7) hours. The volume of distribution and clearance after oral administration of tamsulosin were 0.5 L/kg, and 0.04 L/h/kg, respectively. The accumulation ratios for 0.2 mg once-daily dosing regimen were 1.2. The 90% CIs of the geometric mean ratios for the log-transformed AUC τ (1.005-1.131) and C ss, max (1.000-1.136) values were within the acceptable range for bioequivalence. No serious AE was reported during the study. Both formulations were well tolerated.
third-generation α 1 -adrenoceptor antagonist. 6) Tamsulosin has a moderately higher affinity for the α 1A -adrenoreceptor subtype, which is predominantly distributed in the prostate, bladder neck, and urethra, than for the α 1B subtype in vascular tissues. 7, 8) The chemical structure of tamsulosin is shown in Figure 1 .
Tamsulosin is usually administered once daily as a capsule in a modified-release (MR) formulation, at a dose of 0.2 mg in Japan and other Asian countries and a dose of 0.4 mg in Europe and the US. 9) When administered orally to fasted humans, the absolute bioavailability of tamsulosin MR is approximately 100 %, with a time to reach peak plasma concentration (t max ) ranging from 2.9 to 5.6 h, and a mean terminal half-life of approximately 11.7-22.0 h. 6, 10) Tamsulosin has been reported to exhibit linear pharmacokinetics following single and multiple doses. 9) Tamsulosin is highly bound to plasma proteins (98.9-99.1 %), with most binding to α 1 -acid glycoprotein. [10] [11] [12] Practice. Before participating, all the subjects received written and oral information on the study and signed a consent document.
Study Design
This randomized, open-label, two-period, multiple-dose, crossover study was conducted at Co., Ltd., Seoul, Republic of Korea).
Analysis of Tamsulosin Concentrations
Plasma concentrations of tamsulosin were determined using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC/MS/MS). Briefly, 200 μL of plasma sample was pipetted into a polypropylene tube, and 10 μL of rac tamsulosinmethyl-d3 hydrochloride (30 ng/mL in acetonitrile) was added as an internal standard.
The mixture was then vortexed. After addition of 500 μL acetonitrile, the mixture was vortexed for 5 min, and centrifuged (13,000 rpm, 5 min). 
Pharmacokinetic Analysis
The PK parameters of tamsulosin were determined by non-compartmental methods, using Treatment-emergent adverse events (TEAEs)
were defined as those occurring on or after administration of the first randomized dose.
TEAEs were evaluated by the study physicians in terms of intensity (mild, moderate, severe), duration, severity, outcome, and relationship to the study drug administered.
Statistical Analyses
The results are expressed as means ± SD unless otherwise indicated, and a p-value below 
RESULTS
In total, 44 healthy Korean male subjects reported that the mean (SD) t max in the fasted state ranged from 4.5 to 8.0 (0.7-1.05) h. 6, 9, 16, 17) In the present study, the t max of the test formulation was shorter, with statistical significance, than that of the reference formulation (p = 0.0002). This finding might have been the result of differences in the preparation technologies between the test and reference formulations.
The mean t 1/2 obtained in this study was 9.5 -10.0 h for the two formulations. These findings are consistent with those previously reported. 8, 9) Individual half-lives ranged from 6.1 to 19.7 h, so the 10-day washout period was sufficient because it was longer than five half-lives for all subjects.
The present study has some limitations that should be considered, including the small sample size, short duration of follow-up, open-label design, and data from only healthy male subjects.
Our study demonstrates that the C ss,max and AUC τ values in the fasted subjects were higher than those in the fed from other study, with a shorter t max values. 
